Mind Medicine (MindMed) Inc., a biopharmaceutical company focusing on treatments for brain health disorders, has announced the issuance of inducement grants to four newly hired non-executive employees. These grants consist of options to purchase a total of 128,750 common shares of the company. The options, effective from June 2, 2025, and June 9, 2025, depending on the employee's start date, are set at an exercise price equal to the closing price of MindMed's common shares on the last trading day before the grant date. The vesting schedule for these options spans four years, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in substantially equal monthly increments over the following three years, contingent upon continued employment. These inducement grants were approved by MindMed's Compensation Committee under NASDAQ's rules.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.